DANCANN PHARMA A/S: Financial statements 2023
CVR: 39426005
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
DANCANN PHARMA A/S (CVR 39426005) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -5,299,000 and a net result of DKK -62,260,000 compared with DKK -16,064,000 the year before. Equity in the 2023 report amounted to DKK 9,506,000. The solvency ratio was 53.7%. The company had 12 employees in the financial year.
- Revenue
- DKK 0
- Gross Profit
- DKK -5,299,000
- Profit/Loss
- DKK -62,260,000
- Equity
- DKK 9,506,000
- Total Assets
- DKK 17,710,000
- Employees
- 12
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 0 | -5.3 mio. | -62.3 mio. | 9.5 mio. | 12 |
| 2022 | 0 | -7.6 mio. | -16.1 mio. | 62.8 mio. | 10 |
| 2021 | 0 | -6.8 mio. | -11.8 mio. | 53.4 mio. | 10 |
| 2020 | - | -4.8 mio. | -4.3 mio. | 44.3 mio. | 4 |
| 2019 | - | -422 t. | -1.2 mio. | -1.4 mio. | 4 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of October 26, 2023, Louise Bertelsen Forman has left the board of directors of DANCANN PHARMA A/S.
As of October 26, 2023, Alexander Schoeneck has left the board of directors of DANCANN PHARMA A/S.
DANCANN PHARMA A/S has published its annual report for 2022. Revenue came to DKK 0, and the net result was DKK -16,064,000.
As of May 30, 2023, Louise Bertelsen Forman has joined the board of directors of DANCANN PHARMA A/S.
As of May 30, 2023, Tue Østergaard has left the board of directors of DANCANN PHARMA A/S.
About DANCANN PHARMA A/S
DANCANN PHARMA A/S is a Danish company of the type Aktieselskab based in Ansager, founded in 2018. The company is under bankruptcy. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named DANCANN PHARMA ApS and DANCANN PHARMA IVS. The company is owned by JEQ Capital AB. The company has 1 employee (2026). In 2024, the company reported a gross profit of DKK -148,000 and a net result of DKK -8,346,000 compared with DKK -62,260,000 the year before. Equity in the 2024 report amounted to DKK 14,620,000.